ROIV FDA approval of LISRAYA for dermatomyositis; launches immediately
ROIV says the FDA approved LISRAYA as the first oral targeted therapy for dermatomyositis, with launch immediately.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.